Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
about
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitroBiological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.Deciphering the distance to antibiotic resistance for the pneumococcus using genome sequencing dataActivities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistanceEvaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates.Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genesAlterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitrogyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae.Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococciParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE lociIn vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada.Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory seBenchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniaeGenetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeAntimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.Longitudinal assessment of antipneumococcal susceptibility in the United States.Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniaeDevelopment of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniaeIn vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.The use of platensimycin and platencin to fight antibiotic resistance.The fluoroquinolone levofloxacin triggers the transcriptional activation of iron transport genes that contribute to cell death in Streptococcus pneumoniae.Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Primary targets of fluoroquinolones in Streptococcus pneumoniae.Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faeciumContribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
P2860
Q24673222-EDA9D121-911C-4A15-BDB6-B3C68762E953Q30251593-CB4A047A-7134-45C7-8000-A9356AD5DD71Q31162440-28AAAC2F-BAB6-4508-9BA1-3E60061F80FDQ33593776-788623AA-9FF5-4A42-9442-CEA091808A71Q33594174-97276459-3A44-4596-BBCE-D3DF269AC9B6Q33595145-B4511E01-F621-4C32-8855-E020AB9AC3AAQ33659832-EBD87280-1FB8-454B-871F-62B8285AE706Q33694924-29792FD3-8DF7-411E-92BA-46334970AD70Q33695625-62E67580-0D00-4C8B-BE0B-172308BCFB7CQ33696730-AC89F362-9E6D-4153-8976-D08DD480E213Q33699643-64DFC6B6-139D-4892-B7B2-5BFDF3D28C96Q33700561-C7DB3FF4-E381-4FA5-BF91-D2C4778A46F8Q33976037-8BBE8BC0-AB2A-4C12-8C00-4D2DAF9F4051Q33976055-940FC5F4-8680-4099-A559-377790BD4486Q33976279-05D2F3A2-A8D6-44EE-8A47-F7D44AC21F89Q33977709-627CF289-0959-4159-96A1-AFF6E6006AEBQ33977877-87432FB9-4BDB-441C-89E8-9C7FE37318FCQ33978324-DF6BE72E-67BA-4C07-A564-08D88A9167D2Q33978849-FF3942C0-5710-44B0-A6FC-EA9E31BAEB16Q33980689-102F660D-B64A-43B8-A3EA-AE25870068E0Q33980747-C80422A1-BB79-4695-B1FF-582349DF05A9Q33981638-D06E8528-9AD2-4157-A617-C61144C1340EQ33981750-D8A86F86-4FD5-4919-8F68-D8896E2FF2D3Q33982417-52A0778B-0EE1-4E25-8FB2-1AAC7EE8D45DQ33983643-36A9C502-62ED-40A8-8B79-CB884B59F70DQ34107785-6545DCB8-87C3-4F18-906E-E6B03E3C4D65Q34110932-D3E1B1DB-5EBE-4377-883E-14461F472BAFQ34113933-9A8DC7DA-8C46-4539-B85D-1A41141FF6AAQ35102420-629323C4-B475-4E6F-AE8D-3068C90562B6Q35129221-CFF151BF-9164-46CD-BE5D-F9582B7C4FDDQ35136293-F2B8E3EA-F722-4418-81C1-ABA31DAC5FC8Q36048301-131F9DDB-D727-4AAE-831A-4ABF6D6F6387Q37203095-61860775-20D8-4B73-A840-C6E673FD554DQ37544432-38FAAF49-B284-4296-BDC4-CDABEE70EBDCQ37568953-027495A5-EF03-4A50-83FF-AEA124F0E3F5Q39469902-BD07251D-E9E0-4FD4-B56B-DAF4D0706F50Q39470064-782117DE-29A2-4C1D-A537-B7F1F36901EFQ39470617-38A1C5B6-2F54-4550-B648-D538AA2735BFQ39471518-4CC07A24-CFE3-4E18-987E-B0E15AA3917EQ39472105-566CE953-593A-4588-9FE3-7C5A8BD03300
P2860
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Contribution of mutations in g ...... obtained in vivo and in vitro.
@ast
Contribution of mutations in g ...... obtained in vivo and in vitro.
@en
type
label
Contribution of mutations in g ...... obtained in vivo and in vitro.
@ast
Contribution of mutations in g ...... obtained in vivo and in vitro.
@en
prefLabel
Contribution of mutations in g ...... obtained in vivo and in vitro.
@ast
Contribution of mutations in g ...... obtained in vivo and in vitro.
@en
P2093
P2860
P1476
Contribution of mutations in g ...... obtained in vivo and in vitro.
@en
P2093
P2860
P304
P407
P577
1996-11-01T00:00:00Z